Mannkind (MNKD) Depreciation & Amortization (CF) (2010 - 2026)
Mannkind's (MNKD) quarterly Depreciation & Amortization (CF) came in at $6.4 million in Q1 2026, up 203.04% year-on-year from $2.1 million in Q1 2025, and up 5.84% on a QoQ basis from $6.0 million in Q4 2025.
Mannkind (MNKD) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Mannkind (MNKD) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $6.4 million in Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) rose 203.04% year-over-year to $6.4 million in Q1 2026; TTM through Mar 2026 was $16.6 million, a 104.04% increase from a year earlier, with the FY2025 full-year figure at $12.3 million, up 66.65% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $6.4 million, up from $6.0 million in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for MNKD reached as high as $6.4 million in Q1 2026 and fell as low as $599000.0 in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $2.0 million across 5 years, with a median of $1.4 million in 2024.
- Across the five-year window, Depreciation & Amortization (CF) retreated 28.44% in 2022 and jumped 203.04% in 2026, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $1.0 million in 2022, then increased by 20.45% to $1.2 million in 2023, then soared by 76.33% to $2.2 million in 2024, then soared by 179.17% to $6.0 million in 2025, then increased by 5.84% to $6.4 million in 2026.
- Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $6.4 million in Q1 2026, $6.0 million in Q4 2025, and $2.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Mannkind | 1.20 Bn | 1.07 Bn | 82.66 Mn | 6.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.38 Mn |
| Mar 31, 2026 | 6.38 Mn |
| Dec 31, 2025 | 6.03 Mn |
| Dec 31, 2025 | 6.03 Mn |
| Sep 30, 2025 | 2.06 Mn |
| Sep 30, 2025 | 2.06 Mn |
| Jun 30, 2025 | 2.09 Mn |
| Jun 30, 2025 | 2.09 Mn |
| Mar 31, 2025 | 2.11 Mn |
| Mar 31, 2025 | 2.11 Mn |
| Dec 31, 2024 | 2.16 Mn |
| Dec 31, 2024 | 2.16 Mn |
| Sep 30, 2024 | 2.12 Mn |
| Sep 30, 2024 | 2.12 Mn |
| Jun 30, 2024 | 1.73 Mn |
| Jun 30, 2024 | 1.73 Mn |
| Mar 31, 2024 | 1.36 Mn |
| Mar 31, 2024 | 1.36 Mn |
| Dec 31, 2023 | 1.23 Mn |
| Dec 31, 2023 | 1.23 Mn |